Back to Search Start Over

Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients.

Authors :
Lui DTW
Lee CH
Chow WS
Lee ACH
Tam AR
Cheung CYY
Fong CHY
Kwok STM
Law CY
To KKW
Lam CW
Tan KCB
Woo YC
Hung IFN
Lam KSL
Source :
Journal of endocrinological investigation [J Endocrinol Invest] 2022 Nov; Vol. 45 (11), pp. 2149-2156. Date of Electronic Publication: 2022 Jul 13.
Publication Year :
2022

Abstract

Purpose: Thyroid dysfunction in COVID-19 carries clinical and prognostic implications. In this study, we developed a prediction score (ThyroCOVID) for abnormal thyroid function (TFT) on admission amongst COVID-19 patients.<br />Methods: Consecutive COVID-19 patients admitted to Queen Mary Hospital were prospectively recruited during July 2020-May 2021. Thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) were measured on admission. Multivariable logistic regression analysis was performed to identify independent determinants of abnormal TFTs. ThyroCOVID was developed based on a clinical model with the lowest Akaike information criteria.<br />Results: Five hundred and forty six COVID-19 patients were recruited (median age 50 years, 45.4% men, 72.9% mild disease on admission). 84 patients (15.4%) had abnormal TFTs on admission. Patients with abnormal TFTs were more likely to be older, have more comorbidities, symptomatic, have worse COVID-19 severity, higher SARS-CoV-2 viral loads and more adverse profile of acute-phase reactants, haematological and biochemical parameters. ThyroCOVID consisted of five parameters: symptoms (malaise), comorbidities (ischaemic heart disease/congestive heart failure) and laboratory parameters (lymphocyte count, C-reactive protein, and SARS-CoV-2 cycle threshold values). It was able to identify abnormal TFT on admission with an AUROC of 0.73 (95% CI 0.67-0.79). The optimal cut-off of 0.15 had a sensitivity of 75.0%, specificity of 65.2%, negative predictive value of 93.5% and positive predictive value of 28.1% in identifying abnormal TFTs on admission amongst COVID-19 patients.<br />Conclusion: ThyroCOVID, a prediction score to identify COVID-19 patients at risk of having abnormal TFT on admission, was developed based on a cohort of predominantly non-severe COVID-19 patients.<br /> (© 2022. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).)

Details

Language :
English
ISSN :
1720-8386
Volume :
45
Issue :
11
Database :
MEDLINE
Journal :
Journal of endocrinological investigation
Publication Type :
Academic Journal
Accession number :
35831586
Full Text :
https://doi.org/10.1007/s40618-022-01854-y